Results 91 to 100 of about 120,528 (253)

LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1

Advanced Science, EarlyView.
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li, Tao Wang, Yuwen Zhong, Zhiming Wang, Wei Li, Zejian Wang, Xinyi Yang, Yu Qiao, Jianfeng Xiang, Wei Gu, Zishu Wang, Lei Sun, Feng Qian   +12 more
wiley   +1 more source

Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript [PDF]

, 2011
Genome-wide association studies (GWAS) have identified more than 30 prostate cancer (PrCa) susceptibility loci. One of these (rs2735839) is located close to a plausible candidate susceptibility gene, KLK3, which encodes prostate-specific antigen (PSA)
Castro, E., Donovan, Jenny, Spurdle, A.B., M. Tymrakiewicz, S. J. Chanock, R. Wilkinson, Clements, J. A., Severi, G., J. Batra, Sawyer, E., A. Amin Al Olama, J. L. Hopper, N. Mahmud, Neal, David E., E. Sawyer, Giles, Graham, O'Brien, L., Sit, K. C., Chanock, S.J., Guy, M., Easton, Douglas F., Amin Al Olama, A., F. Hamdy, Hamdy, Freddie C., Clements, J.A., R. A. Eeles, Pharoah, P. D. P., Leongamornlert, D., G. Severi, Giles, G.G., D. Neal, Hall, A., P. D. P. Pharoah, Tymrakiewicz, M., Z. Kote-Jarai, M. Southey, Hopper, J. L., Benlloch, S., Batra, J., E. Castro, E. Saunders, Hopper, J.L., Muir, Kenneth, Eeles, R.A., Al Olama, A.A., D. F. Easton, G. G. Giles, K. C. Sit, Wilkinson, R., Harris, J.M., Muir, K., Easton, D.F., A. B. Spurdle, A. Hall, J. A. Clements, Sit, K.C., Pharoah, P.D.P., J. M. Harris, Brown, N., Neal, D., Mahmud, N., Hamdy, F., Harris, J. M., L. O’Brien, Donovan, J., S. Benlloch, D. Leongamornlert, M. Guy, Saunders, E., Spurdle, A. B., K. Muir, Chanock, Stephen, Southey, M., N. Brown, J. Donovan, Kote-Jarai, Z., Eeles, Rosalind A.   +76 more
core   +1 more source

rWTC‐MBTA Vaccine, Alone and Enhanced with Anti‐PD1, Elicits Immune Responses against CNS and Peripheral B‐Cell Lymphoma

Advanced Science, EarlyView.
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang, Juan Ye, Mitchell Sun, Samik Chakraborty, Alex Valenzuela, Shuran Chen, Qingfeng Xue, Wenyu Shi, Karel Pacak, Herui Wang, Zhengping Zhuang   +10 more
wiley   +1 more source

Development of prostrate cancer vaccine using PAP as target antigen

, 2014
Treatment options for patients with advanced prostate cancer (PC) still remain limited and rarely curative. The prostatic acid phosphatase (PAP) is prostate specific protein over-expressed in more than 90% of prostate tumours.
Javad, JMS
core  

β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto, Deborah Silverman, Tongxin Xie, Shamima Akhter, Nicole R. Vaughn, Adewale Adebayo, Kala Chand Debnath, Shorook Naara, Shajedul Islam, Erik Knutsen, Emily Lorin Ashkin, Simone Anfossi, Sara Leahey, Patrick Hwu, Sebastien Talbot, Erica K Sloan, Robert Saddawi‐Konefka, Roberto Rangel, Jeffrey N. Myers, George A. Calin, Moran Amit   +20 more
wiley   +1 more source

Metastatic prostate cancer in the modern era of PSA screening

International Brazilian Journal of Urology
Introduction To characterize initial presentation and PSA screening status in a contemporary cohort of men treated for metastatic prostate cancer at our institution.
Philip A. Fontenot Jr, Avinash Nehra, William Parker, Hadley Wyre, Moben Mirza, David A. Duchene, Jeffrey Holzbeierlein, James Brantley Thrasher, Peter Van Veldhuizen, Eugene K. Lee   +9 more
doaj   +1 more source

PET Imaging of Cardiac Inflammation in Viral Myocarditis Using a DPP4‐Targeted Probe

Advanced Science, EarlyView.
This study describes a DPP4‐targeted PET probe for imaging myocardial inflammation by selectively targeting activated immune cells. Derived from the clinically approved small‐molecule inhibitor linagliptin, the probe demonstrates favorable biodistribution with specific cardiac uptake in myocarditis.
Wanhao Gao, Wenzhu Hu, Du Tang, Xinxin Liu, Kun Yu, Lixia Feng, Minyu Liao, Wang Lin, Wenqiang Zhu, Sanjay Rajagopalan, Xiaoli Lan, Jixin Zhong, Dao Wen Wang, Dawei Jiang, Xiaoquan Rao   +14 more
wiley   +1 more source

Prostate cancer in Australia [PDF]

, 2013
This is the first comprehensive national report on prostate cancer in Australia, presenting an overview of the condition and analysis of key summary measures including incidence, mortality and survival.SummaryThe effect of prostate cancer is wide ...

core  

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Research of the best screen interval for middle aged and elderly Chinese males with baseline prostate specific antigen levels <2.0 ng/mL in prostate cancer screening [PDF]

Journal of Men's Health
This study aimed to investigate the optimal screening interval of a prostate specific antigen (PSA) screening program for men aged 40–70 with a baseline PSA 10 ng/mL, or 4–10 ng/mL (gray area) and f/t PSA
Yu Chen, Gansheng Xie, Gang Li, Yu Li
doaj   +1 more source